NorthWest Biotherapeutics Inc (NWBO)

[anders2211]

Even IDH mutant or IDH wild type status were not part of the protocol. It's possible that it may receive some sort of mention in the journal, but a deeper analysis will likely be addressed in some sort of future white paper.

Mmm, if the IDH mutant is not counted as GBM on the orders of the WHO, then this will have an impact on those that survived the true definition of GBM and thus does play a huge role in the primary endpoint, or am I wrong?.

But the many pages in-depth long paper will be a white one not in the journal true.